Targeting Antigens for Universal Influenza Vaccine Development
Traditional influenza vaccines generate strain-specific antibodies which cannot provide protection against divergent influenza virus strains. Further, due to frequent antigenic shifts and drift of influenza viruses, annual reformulation and revaccination are required in order to match circulating st...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/6/973 |
id |
doaj-ce7ac2d27a8a43e8973598249726ed17 |
---|---|
record_format |
Article |
spelling |
doaj-ce7ac2d27a8a43e8973598249726ed172021-06-01T00:58:46ZengMDPI AGViruses1999-49152021-05-011397397310.3390/v13060973Targeting Antigens for Universal Influenza Vaccine DevelopmentQuyen-Thi Nguyen0Young-Ki Choi1College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, KoreaCollege of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, KoreaTraditional influenza vaccines generate strain-specific antibodies which cannot provide protection against divergent influenza virus strains. Further, due to frequent antigenic shifts and drift of influenza viruses, annual reformulation and revaccination are required in order to match circulating strains. Thus, the development of a universal influenza vaccine (UIV) is critical for long-term protection against all seasonal influenza virus strains, as well as to provide protection against a potential pandemic virus. One of the most important strategies in the development of UIVs is the selection of optimal targeting antigens to generate broadly cross-reactive neutralizing antibodies or cross-reactive T cell responses against divergent influenza virus strains. However, each type of target antigen for UIVs has advantages and limitations for the generation of sufficient immune responses against divergent influenza viruses. Herein, we review current strategies and perspectives regarding the use of antigens, including hemagglutinin, neuraminidase, matrix proteins, and internal proteins, for universal influenza vaccine development.https://www.mdpi.com/1999-4915/13/6/973influenzauniversal vaccineantigenimmune response |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Quyen-Thi Nguyen Young-Ki Choi |
spellingShingle |
Quyen-Thi Nguyen Young-Ki Choi Targeting Antigens for Universal Influenza Vaccine Development Viruses influenza universal vaccine antigen immune response |
author_facet |
Quyen-Thi Nguyen Young-Ki Choi |
author_sort |
Quyen-Thi Nguyen |
title |
Targeting Antigens for Universal Influenza Vaccine Development |
title_short |
Targeting Antigens for Universal Influenza Vaccine Development |
title_full |
Targeting Antigens for Universal Influenza Vaccine Development |
title_fullStr |
Targeting Antigens for Universal Influenza Vaccine Development |
title_full_unstemmed |
Targeting Antigens for Universal Influenza Vaccine Development |
title_sort |
targeting antigens for universal influenza vaccine development |
publisher |
MDPI AG |
series |
Viruses |
issn |
1999-4915 |
publishDate |
2021-05-01 |
description |
Traditional influenza vaccines generate strain-specific antibodies which cannot provide protection against divergent influenza virus strains. Further, due to frequent antigenic shifts and drift of influenza viruses, annual reformulation and revaccination are required in order to match circulating strains. Thus, the development of a universal influenza vaccine (UIV) is critical for long-term protection against all seasonal influenza virus strains, as well as to provide protection against a potential pandemic virus. One of the most important strategies in the development of UIVs is the selection of optimal targeting antigens to generate broadly cross-reactive neutralizing antibodies or cross-reactive T cell responses against divergent influenza virus strains. However, each type of target antigen for UIVs has advantages and limitations for the generation of sufficient immune responses against divergent influenza viruses. Herein, we review current strategies and perspectives regarding the use of antigens, including hemagglutinin, neuraminidase, matrix proteins, and internal proteins, for universal influenza vaccine development. |
topic |
influenza universal vaccine antigen immune response |
url |
https://www.mdpi.com/1999-4915/13/6/973 |
work_keys_str_mv |
AT quyenthinguyen targetingantigensforuniversalinfluenzavaccinedevelopment AT youngkichoi targetingantigensforuniversalinfluenzavaccinedevelopment |
_version_ |
1721413448595668992 |